Lipid-lowing pharmacogenomics in Chinese patients.
Pharmacogenomic studies on statins ranging from the candidate gene approach to the genome-wide studies in western populations have provided evidence that genetic variations play a limited role in determining statin responses. However, there are ethnic difference in the pharmacokinetics and safety of statins and due to the different frequencies of polymorphisms and different linkage disequilibrium patterns among the ethnic groups, the genetic markers identified in genome-wide association study platforms or in candidate gene studies in one population cannot always be generalized to other populations. This review provides an overview on the pharmacogenomics of statins in Chinese population.